228 related articles for article (PubMed ID: 26764354)
1. Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy.
Liu YL; Yan Y; Webster C; Shao L; Lensing SY; Ni H; Feng W; Colorado N; Pathak R; Xiang Z; Hauer-Jensen M; Li S; Zhou D; Emanuel PD
Blood; 2016 Apr; 127(15):1912-22. PubMed ID: 26764354
[TBL] [Abstract][Full Text] [Related]
2. Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
Akutagawa J; Huang TQ; Epstein I; Chang T; Quirindongo-Crespo M; Cottonham CL; Dail M; Slusher BS; Friedman LS; Sampath D; Braun BS
Leukemia; 2016 Jun; 30(6):1335-43. PubMed ID: 26965285
[TBL] [Abstract][Full Text] [Related]
3. [Juvenile myelomonocytic leukemias].
Lachenaud J; Strullu M; Baruchel A; Cavé H
Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
[TBL] [Abstract][Full Text] [Related]
4. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.
Chan RJ; Leedy MB; Munugalavadla V; Voorhorst CS; Li Y; Yu M; Kapur R
Blood; 2005 May; 105(9):3737-42. PubMed ID: 15644411
[TBL] [Abstract][Full Text] [Related]
5. Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.
Sachs Z; Been RA; DeCoursin KJ; Nguyen HT; Mohd Hassan NA; Noble-Orcutt KE; Eckfeldt CE; Pomeroy EJ; Diaz-Flores E; Geurts JL; Diers MD; Hasz DE; Morgan KJ; MacMillan ML; Shannon KM; Largaespada DA; Wiesner SM
Haematologica; 2016 Oct; 101(10):1190-1199. PubMed ID: 27418650
[TBL] [Abstract][Full Text] [Related]
6. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.
Chan G; Kalaitzidis D; Usenko T; Kutok JL; Yang W; Mohi MG; Neel BG
Blood; 2009 Apr; 113(18):4414-24. PubMed ID: 19179468
[TBL] [Abstract][Full Text] [Related]
7. VAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease.
An W; Mohapatra BC; Zutshi N; Bielecki TA; Goez BT; Luan H; Iseka F; Mushtaq I; Storck MD; Band V; Band H
Oncotarget; 2016 Sep; 7(37):59006-59016. PubMed ID: 27449297
[TBL] [Abstract][Full Text] [Related]
8. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
Yoshida N; Yagasaki H; Xu Y; Matsuda K; Yoshimi A; Takahashi Y; Hama A; Nishio N; Muramatsu H; Watanabe N; Matsumoto K; Kato K; Ueyama J; Inada H; Goto H; Yabe M; Kudo K; Mimaya J; Kikuchi A; Manabe A; Koike K; Kojima S
Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918
[TBL] [Abstract][Full Text] [Related]
9. Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.
Yoshida N; Doisaki S; Kojima S
Paediatr Drugs; 2012 Jun; 14(3):157-63. PubMed ID: 22480363
[TBL] [Abstract][Full Text] [Related]
10. Leukemic potential of doubly mutant Nf1 and Wv hematopoietic cells.
Ingram DA; Wenning MJ; Shannon K; Clapp DW
Blood; 2003 Mar; 101(5):1984-6. PubMed ID: 12393498
[TBL] [Abstract][Full Text] [Related]
11. Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice.
Tarnawsky SP; Yoshimoto M; Deng L; Chan RJ; Yoder MC
Dev Dyn; 2017 Dec; 246(12):1001-1014. PubMed ID: 28975680
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.
Bunda S; Kang MW; Sybingco SS; Weng J; Favre H; Shin DH; Irwin MS; Loh ML; Ohh M
Cancer Res; 2013 Apr; 73(8):2540-50. PubMed ID: 23400592
[TBL] [Abstract][Full Text] [Related]
13. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.
Loh ML; Vattikuti S; Schubbert S; Reynolds MG; Carlson E; Lieuw KH; Cheng JW; Lee CM; Stokoe D; Bonifas JM; Curtiss NP; Gotlib J; Meshinchi S; Le Beau MM; Emanuel PD; Shannon KM
Blood; 2004 Mar; 103(6):2325-31. PubMed ID: 14644997
[TBL] [Abstract][Full Text] [Related]
14. Constitutive MAP kinase activation in hematopoietic stem cells induces a myeloproliferative disorder.
Chung E; Hsu CL; Kondo M
PLoS One; 2011; 6(12):e28350. PubMed ID: 22164275
[TBL] [Abstract][Full Text] [Related]
15. Nf1 and Gmcsf interact in myeloid leukemogenesis.
Birnbaum RA; O'Marcaigh A; Wardak Z; Zhang YY; Dranoff G; Jacks T; Clapp DW; Shannon KM
Mol Cell; 2000 Jan; 5(1):189-95. PubMed ID: 10678181
[TBL] [Abstract][Full Text] [Related]
16. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
Yoshimi A; Balasis ME; Vedder A; Feldman K; Ma Y; Zhang H; Lee SC; Letson C; Niyongere S; Lu SX; Ball M; Taylor J; Zhang Q; Zhao Y; Youssef S; Chung YR; Zhang XJ; Durham BH; Yang W; List AF; Loh ML; Klimek V; Berger MF; Stieglitz E; Padron E; Abdel-Wahab O
Blood; 2017 Jul; 130(4):397-407. PubMed ID: 28576879
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment.
Leoncini PP; Bertaina A; Papaioannou D; Flotho C; Masetti R; Bresolin S; Menna G; Santoro N; Zecca M; Basso G; Nigita G; Veneziano D; Pagotto S; D'Ovidio K; Rota R; Dorrance A; Croce CM; Niemeyer C; Locatelli F; Garzon R
Oncotarget; 2016 Aug; 7(34):55395-55408. PubMed ID: 27447965
[TBL] [Abstract][Full Text] [Related]
18. Functional evaluation of circulating hematopoietic progenitors in Noonan syndrome.
Timeus F; Crescenzio N; Baldassarre G; Doria A; Vallero S; Foglia L; Pagliano S; Rossi C; Silengo MC; Ramenghi U; Fagioli F; Cordero di Montezemolo L; Ferrero GB
Oncol Rep; 2013 Aug; 30(2):553-9. PubMed ID: 23756559
[TBL] [Abstract][Full Text] [Related]
19. Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice.
Kim A; Morgan K; Hasz DE; Wiesner SM; Lauchle JO; Geurts JL; Diers MD; Le DT; Kogan SC; Parada LF; Shannon K; Largaespada DA
Blood; 2007 Feb; 109(4):1687-91. PubMed ID: 17090653
[TBL] [Abstract][Full Text] [Related]
20. Targeting Raf-1 gene expression by a DNA enzyme inhibits juvenile myelomonocytic leukemia cell growth.
Iversen PO; Emanuel PD; Sioud M
Blood; 2002 Jun; 99(11):4147-53. PubMed ID: 12010819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
